ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions.

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

When should you not nasal rinse? While most people can benefit from a nasal rinse, it won’t work if you have severe inflammation in your nose blocking the nasal passages. Smith suggests using a ...

The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment ... meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 ...

After four weeks, 22.5 percent of patients taking Spravato achieved remission (score ≤12 on MADRS) compared with 7.6 percent of patients taking placebo. Spravato nasal spray is administered by ...

Rep. Mike Collins (R-Ga.) heavily criticized statements made by the Right Rev. Mariann Budde on Tuesday at the inaugural prayer service held for President Trump. “The person giving this sermon should ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine ... depressive symptoms as early as 24 hours and at 28 days—without the ...